These data emphasize our initial assumption that IL-11RA represents the amplification target rather than DCTN3. This hypothesis is further strengthened by immunohistochemical studies [29], [30] and the cancer profiling database OncomineTM (www.oncomine.org) which both reveal high overexpression of IL-11RA in prostate cancer compared to normal prostate tissue. This evidence concerns the gene IL11RA and prostate carcinoma.